Filing Details

Accession Number:
0000950170-25-009941
Form Type:
13G Filing
Publication Date:
2025-01-27 19:00:00
Filed By:
Unique Diamond Investments Limited
Company:
Cg Oncology Inc.
Filing Date:
2025-01-28
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Unique Diamond Investments Limited 0 586,982 0.8%
ORI Healthcare Fund, L.P. 0 586,982 0.8%
ORI Capital Inc. 0 586,982 0.8%
ORI Capital Holding Inc. 0 586,982 0.8%
Charming Jade Limited 0 3,003,931 4%
ORI Healthcare Fund II, L.P. 0 3,003,931 4%
ORI Capital II Inc. 0 3,003,931 4%
ORI Holding II Inc. 0 3,003,931 4%
Healthcare Seed Limited 0 3,590,913 4.7%
SONG, Hong Fang 0 4,211,341 5.5%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common stock, $0.0001 par value per share ("Common Stock") outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G



Comment for Type of Reporting Person:  *This calculation is based on 76,037,858 shares of Common Stock outstanding as of December 16, 2024, as disclosed in the Issuer's Form 424B4 Prospectus filed by the Company on December 13, 2024 based on the number of shares of Common Stock to be outstanding if the underwriters exercised their option to purchase additional shares of Common Stock in full.


SCHEDULE 13G


 
Unique Diamond Investments Limited
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang/Director
Date:01/28/2025
 
ORI Healthcare Fund, L.P.
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang/Director
Date:01/28/2025
 
ORI Capital Inc.
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang/Director
Date:01/28/2025
 
ORI Capital Holding Inc.
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang/Director
Date:01/28/2025
 
Charming Jade Limited
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang/Director
Date:01/28/2025
 
ORI Healthcare Fund II, L.P.
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang/Director of General Partner
Date:01/28/2025
 
ORI Capital II Inc.
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang/Director
Date:01/28/2025
 
ORI Holding II Inc.
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang/Director
Date:01/28/2025
 
Healthcare Seed Limited
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang/Director
Date:01/28/2025
 
SONG, Hong Fang
 
Signature:/s/ SONG, Hong Fang
Name/Title:SONG, Hong Fang
Date:01/28/2025